Reported Earlier, Daiichi Sankyo And AstraZeneca Initiate TROPION-Lung12 Phase 3 Trial To Evaluate DATROWAY In Adjuvant Treatment for High-Risk Early-Stage NSCLC

Author: Benzinga Newsdesk | January 31, 2025 01:45am

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (NASDAQ:AZN).

Standard treatment for stage 1 NSCLC is tumor resection, but up to 40% of patients may experience disease recurrence.1,2,3 Tumor resection is typically followed by observation but adjuvant chemotherapy and/or immunotherapy may be offered to patients with stage 1b disease who are identified to be at high risk of relapse.4 However, novel strategies to identify high risk patients are needed as well as additional treatment options in the adjuvant setting. Research suggests that ctDNA screening may help identify high risk patients who are most likely to benefit from adjuvant therapy.5,6

Posted In: AZN DSNKY